Journal of Medicinal Chemistry p. 1496 - 1504 (1990)
Update date:2022-08-04
Topics:
Reiffen
Eberlein
Muller
Psiorz
Noll
Heider
Lillie
Kobinger
Luger
Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.
View MoreChengdu Green technology Co.,Ltd.
Contact:86-28-82608355
Address:C9 ,Economic Headquarters, Economic Development Zone, Chengdu.
SuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
Nanjing distinctions Medical Technology Co., Ltd.(expird)
Contact:+86-15996203785 13914714059
Address:nanjing,jiangsu , China
FREEBARQUE DEVELOPMENT GROUP LIMITED
Contact:+86(0)10-5109 5335 or 5109 5345
Address:Room602,Block1-B,LINGDI OFFICE,NO.13 BEIYUAN ROAD
Lianyungang Yunbo Chemical Co.,Ltd.
Contact:518-81066110
Address:B907,Dongsheng"Mingdu Square,21-2 East Chaoyang Road,Xinpu,(sale department)
Doi:10.1071/CH03164
(2004)Doi:10.7164/antibiotics.31.933
(1978)Doi:10.1002/ejoc.200300649
(2004)Doi:10.1021/jm030354b
(2004)Doi:10.1021/jm00210a036
(1978)Doi:10.1002/ejoc.200300645
(2004)